ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2076

Predictive Modeling of a Fibromyalgia Diagnosis: Increasing the Accuracy Using Real World Data

Birol Emir1, Jack Mardekian1, Elizabeth T. Masters1, Andrew Clair1, Max Kuhn2 and Stuart L. Silverman3, 1Pfizer Inc, New York, NY, 2Pfizer Inc., Groton, CT, 3Cedars-Sinai Medical Center, UCLA Center of Excellence, Los Angeles, CA

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Data analysis, diagnosis and fibromyalgia, Electronic Health Record

  • Tweet
  • Email
  • Print
Session Information

Title: Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes: Research Focus

Session Type: Abstract Submissions (ACR)

Background/Purpose: The number of symptoms and comorbidities associated with the chronic pain condition of fibromyalgia (FM) complicates its identification and diagnosis.

Methods: This retrospective analysis used structured de-identified electronic health records from the 2011-2012 Humedica database, including demographics, clinical characteristics, and healthcare resource use. An FM cohort was defined as subjects ≥18 years in 2011 with ≥2 ICD-9 codes for FM (729.1) ≥30 days apart during 2012; the no-FM cohort did not have the ICD-9 code. Univariate analyses characterized between-cohort differences and determined the demographic, clinical, and healthcare resource variables associated with an FM diagnosis. A Random Forest (RF) model was used to predict FM and non-FM subjects by entering all variables into the model (1500 bootstraps) with internal down-sampling (to account for imbalance between cohorts). Importance of the variables was computed using RF to determine the trade-off on accuracy when only the top 10 variables were fitted. For practical clinical application, a rule-based model was used to derive simple statements to help explain which patient sets have the largest effect on the likelihood of an FM diagnosis.

Results: Significant differences were observed between the FM (n=4,296) and no-FM (n=583,665) cohorts for demographics (P<.0001) except for age, for most evaluated comorbidities (P<.0001), and for healthcare resource use (P<.0001), with more comorbidities and resource use in FM subjects. Resources included proportions of subjects with utilization, and units used per subject for emergency room visits, outpatient visits, hospitalizations, and medications. The top 10 variables for predicting an FM diagnosis were identified from the RF models based on level of importance as reflected by the percent of model iterations in which the variable was predictive (Figure). A receiver operator characteristic curve confirmed the predictive accuracy of the model variables (area under the curve of 0.810). Rules were developed to identify patients with high predicted probability of an FM diagnosis; e.g., the average predicted probability of 0.54 for a subset of patients with outpatient visits excluding office visits >0 and prescriptions administered/ordered ≤3 and the number of musculoskeletal pain conditions >0 was more than double the 0.22 predicted probability for those not in the subset. Similarly, a rule to identify non-FM (opioid prescriptions administered/ordered/written =0; visits where diagnostic/laboratory tests were ordered =0; and number of musculoskeletal pain conditions =0) correctly classified 100% of the sample.

Conclusion: Random forest modeling can be applied to determine likelihood of an FM diagnosis. Rules can simplify this method with good accuracy. Further validation of RF may help facilitate earlier diagnosis and enhance management strategies.

 


Disclosure:

B. Emir,

Pfizer Inc.,

1,

Pfizer Inc.,

3;

J. Mardekian,

Pfizer Inc.,

1,

Pfizer Inc.,

3;

E. T. Masters,

Pfizer Inc.,

1,

Pfizer Inc.,

3;

A. Clair,

Pfizer Inc.,

1,

Pfizer Inc.,

3;

M. Kuhn,

Pfizer Inc.,

3;

S. L. Silverman,

Amgen, Eli Lilly, Pfizer,

8,

Amgen, Genentech, Eli Lilly, Novartis, Pfizer,

5,

Amgen, Eli Lilly, Medtronics, Pfizer,

2.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/predictive-modeling-of-a-fibromyalgia-diagnosis-increasing-the-accuracy-using-real-world-data/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology